French health authorities have suspended the use of Valneva’s chikungunya vaccine Ixchiq in adults aged 65 and older after ...

Shares of French speciality vaccines developer Valneva (Nasdaq: VAL) were down 8.4% at 2.89 euros by early afternoon, after ...

Shares in Valneva plunged after the company said France's health authorities suspended the use of its chikungunya vaccine, Ixchiq, for people aged 65 and older, raising concerns about the vaccine's ...

As safety flags hang over Valneva’s chikungunya vaccine in the U.S. and beyond, French authorities are clamping down on the shot’s use in older adults. | France’s public health agency has temporarily ...

The country is considered the epicenter of the disease in the Americas, with epidemics reported over the years.

Valneva said it has been supplying Ixchiq to help the French government respond to a major outbreak of chikungunya in La ...

This new agreement complements the license agreement Valneva signed in 2021 with Instituto Butantan in Brazil for the development, manufacturing and marketing of a local chikungunya vaccine at an ...

In the evening of April 22, Valneva will attend the Vaccine Industry Excellence Awards ceremony, where it is a finalist for the Best Biotech Award and Best Prophylactic Vaccine Award for VLA15, the ...

The ANVISA decision marks the world’s first approval of a chikungunya vaccine in an endemic country. Also Read: Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single ...

Valneva has received marketing authorisation from the Brazilian Health Regulatory Agency (ANVISA) for its single-dose chikungunya vaccine, Ixchiq, for individuals aged 18 years and above. This is the ...

Valneva has been responding to the French government’s call for vaccine supply of IXCHIQ® in La Reunion1 as the island is going through a major chikungunya outbreak with ~ 40,000 confirmed ...